Lower mean platelet volume is a risk indicator of hepatocellular carcinoma recurrence following liver transplantation

被引:11
|
作者
Zhang, Ai-Bin [1 ]
Zhang, Zhi-Hao [2 ]
Zhang, Jie [3 ]
Lin, Bing-Yi [1 ,2 ]
Geng, Lei [1 ,2 ]
Yang, Zhe [1 ,2 ]
Feng, Xiao-Ning [1 ]
Zheng, Shu-Sen [1 ,2 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Surg, Div Hepatobiliary & Pancreat Surg,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Key Lab Combined Multiorgan Transplantat, Minist Publ Hlth,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
[3] Jiaxing Univ, Hosp Jiaxing 1, Dept Hepatobiliary Surg, Jiaxing 314000, Peoples R China
关键词
Hepatocellular carcinoma; Mean platelet volume; Liver transplantation; Platelet; Prognosis; ABSOLUTE MONOCYTE COUNT; C-REACTIVE PROTEIN; CANCER-CELLS; PROGNOSIS; DIAGNOSIS;
D O I
10.1016/j.hbpd.2019.04.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Lower mean platelet volume (MPV) is an indicator of platelet activity in the setting of tumor development. This study was to assess the relationship between preoperative MPV and survival outcomes of patients with hepatocellular carcinoma (HCC) following liver transplantation (LT). Methods: The demographic and clinical characteristics of 304 HCC patients following LT were retrieved from an LT database. All the patients were divided into the normal and lower MPV groups according to the median MPV. The factors were first analyzed using a Kaplan-Meier survival analysis, then the factors with P < 0.10 were selected for multivariate Cox regression analysis and were used to define the independent risk factors for poor prognosis. Results: The 1-, 3-, and 5-year tumor free survival was 95.34%, 74.67% and 69.29% in the normal MPV group, respectively, and 95.40%, 59.97% and 42.94% in the lower MPV group, respectively (P < 0.01). No significant difference was observed in post-LT complications between the normal and lower MPV groups. Portal vein tumor thrombosis (PVTT) [hazard ratio (HR =2.24; 95% confidence interval: 1.46-3.43; P < 0.01) and lower MPV (HR =1.58; 95% confidence interval: 1.05-2.36; P=0.03) were identified as independent prognostic risk factors for recipient survival. Conclusion: Preoperative lower MPV is a risk indicator of HCC patients survival outcomes after LT. (C) 2019 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:223 / 227
页数:5
相关论文
共 50 条
  • [31] Hepatocellular Carcinoma Recurrence After Liver Transplantation
    Gabutti, Alejandro
    Bhoori, Sherrie
    Cascella, Tommaso
    Bongini, Marco
    ONCOLOGY-NEW YORK, 2020, 34 (03): : 91 - 94
  • [32] Recurrence of hepatocellular carcinoma after liver transplantation
    Escartin, A.
    Sapisochin, G.
    Bilbao, I.
    Vilallonga, R.
    Bueno, J.
    Castells, L.
    Dopazo, C.
    Castro, E.
    Caralt, M.
    Balsells, J.
    TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) : 2308 - 2310
  • [33] The Role of Mean Platelet Volume in the Diagnosis of Hepatocellular Carcinoma in Patients with Chronic Liver Disease
    Kurt, Mevlut
    Onal, Ibrahim Koral
    Sayilir, Abdurrahim
    Beyazit, Yavuz
    Oztas, Erkin
    Kekilli, Murat
    Turhan, Nesrin
    Karaman, Kerem
    Akdogan, Meral
    HEPATO-GASTROENTEROLOGY, 2012, 59 (117) : 1580 - 1582
  • [34] Clinical Implication of Ischemic Time on Recurrence of Hepatocellular Carcinoma Following Liver Transplantation
    Nagai, S.
    Yoshida, A.
    Brown, L.
    Kazimi, M.
    Kim, D.
    Abouljoud, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 36 - 37
  • [35] Visceral Adiposity Is Associated with Increased Recurrence of Hepatocellular Carcinoma Following Liver Transplantation
    Mathur, Abhishek
    Li Boyangzi
    Prince, Martin
    Guarrera, James
    Samstein, Benjamin
    Griesemer, Adam
    Kato, Tomoaki
    Emond, Jean
    TRANSPLANTATION, 2016, 100 : S83 - S83
  • [36] Peritumoral neutrophil infiltration predicts recurrence of hepatocellular carcinoma following liver transplantation
    Najjar, Marc
    Ross, Michael
    Srivastava, Ayush
    Gartrell, Robyn
    Rizk, Emanuelle
    Perez, Olivia
    Lieberman, Evan
    Drake, Charles
    Fazlollahi, Ladan
    Remotti, Helen
    Verna, Elizabeth
    Halazun, Karim
    Emond, Jean
    Saenger, Yvonne
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [37] Hepatocellular carcinoma recurrence pattern following liver transplantation and a suggested surveillance algorithm
    Scortegagna, Eduardo, Jr.
    Karam, Adib R.
    Sioshansi, Shirin
    Bozorgzadeh, Adel
    Barry, Curtis
    Hussain, Sarwat
    CLINICAL IMAGING, 2016, 40 (06) : 1131 - 1134
  • [38] Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation
    Fisher, R. A.
    Kulik, L. M.
    Freise, C. E.
    Lok, A. S. F.
    Shearon, T. H.
    Brown, R. S., Jr.
    Ghobrial, R. M.
    Fair, J. H.
    Olthoff, K. M.
    Kam, I.
    Berg, C. L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (06) : 1601 - 1608
  • [39] Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation
    Han, Zhong-Bo
    Zhong, Lin
    Teng, Mu-Jian
    Fan, Jun-Wei
    Tang, Hua-Mei
    Wu, Jun-Yi
    Chen, Hong-Yuan
    Wang, Zhao-Wen
    Qiu, Guo-Qiang
    Peng, Zhi-Hai
    MOLECULAR ONCOLOGY, 2012, 6 (04) : 445 - 457
  • [40] Treatment for the recurrence of hepatocellular carcinoma following liver transplantation What is the best strategy?
    Shi, Ying-Hong
    Zhou, Jian
    Fan, Jia
    CANCER BIOLOGY & THERAPY, 2009, 8 (07) : 591 - 593